Vinorelbine
Active ingredient: Vinorelbine Tartrate
In short: Vinorelbine Injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC
What is Vinorelbine used for?
Vinorelbine Injection is indicated:
In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
As a single agent for the treatment of patients with metastatic NSCLC
âš Boxed warning (FDA's strongest warning)
Severe myelosuppression resulting in serious infection, septic shock, hospitalization and death can occur
.
Decrease the dose or withhold vinorelbine in accord with recommended dose modifications
.
Vinorelbine dosage
In Combination with Cisplatin 100 mg/m
2
The recommended dosage of Vinorelbine Injection is 25 mg/m2 administered as an intravenous injection or infusion over 6 to 10 minutes on Days 1, 8, 15 and 22 of a 28-day cycle in combination with cisplatin 100 mg/m2 on Day 1 only of each 28-day cycle.
In Combination with Cisplatin 120 mg/m
2
The recommended dosage of Vinorelbine Injection is 30 mg/m2 administered as an intravenous injection or infusion over 6 to 10 minutes once a week in combination with cisplatin 120 mg/m2 on Days 1 and 29, then every 6 weeks.
Single Agent
The recommended dosage of Vinorelbine Injection is 30 mg/m2 administered intravenously over 6 to 10 minutes once a week.
Myelosuppression
Hold or decrease the dose of Vinorelbine Injection in patients with decreased neutrophil counts according to the following schema :
Neutrophils on Day of Treatment (cells/mm
3
) | Percentage of Starting Dose of Vinorelbine Injection
≥ 1,500 | 100%
1,000 to 1,499 | 50%
< 1,000 | Do not administer Vinorelbine Injection.Repeat neutrophil count in one week.If three consecutive weekly doses are held becauseneutrophil count is < 1,000 cells/mm3, discontinue Vinorelbine Injection
Note: For patients who experience fever and/or sepsis while neutrophil count is < 1,500 cells/mm3 or had 2 consecutive weekly doses held due to neutropenia, subsequent doses of Vinorelbine Injection should be:
> 1,500 | 75%
1,000 to 1,499 | 37.5%
< 1,000 | Do not administer Vinorelbine Injection. Repeat neutrophil count in one week.
Hepatic Impairment/Toxicity
Reduce Vinorelbine Injection dose in patients with elevated serum total bilirubin concentration according to the following schema :
Serum Total Bilirubin Concentration (mg/dl) | Percentage of Starting Dose of
Vinorelbine Injection
≤ 2.0 | 100%
2.1 to 3.0 | 50%
> 3.0 | 25%
Concurrent Myelosuppression and Hepatic Impairment/Toxicity
In patients with both myelosuppression and hepatic impairment/toxicity, administer the lower of the doses based on the corresponding starting dose of Vinorelbine Injection determined from the above schemas.
Neurologic Toxicity
Discontinue Vinorelbine Injection for Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher peripheral neuropathy or autonomic neuropathy causing constipation .
Preparation
Dilute Vinorelbine Injection in an intravenous bag to a concentration between 0.5 mg/mL and 2 mg/mL. …
How to take Vinorelbine — instructions & advice from the label
Myelosuppression
Advise patients to contact a healthcare provider for new onset fever, or symptoms of infection .
Constipation and Bowel Obstruction
Advise patients to follow a diet rich in fibers, drink fluids to stay well hydrated and use stool softeners to avoid constipation. Contact a health care provider for severe constipation, new onset abdominal pain, nausea and vomiting .
Neurologic Toxicity
Advise patients to contact a health care provider for new onset or worsening of numbness, tingling, decrease sensation or muscle weakness .
Pulmonary Toxicity
Advise patients to contact a healthcare provider for new onset or worsening of shortness of breath, cough, wheezing or other new pulmonary symptoms .
Embryo-Fetal Toxicity
Advise pregnant women of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy .
Advise females of reproductive potential to use effective contraception during treatment with Vinorelbine Injection and for 6 months after the final dose . …
Warnings & precautions
Do not take this medicine if: None
Myelosuppression, manifested by neutropenia, anemia and thrombocytopenia, occur in patients receiving vinorelbine as a single agent and in combination with cisplatin . Neutropenia is the major dose-limiting toxicity with vinorelbine. Grade 3-4 neutropenia occurred in 53% of patients treated with vinorelbine at 30 mg/m2 per week. Dose adjustment due to myelosuppression occurred in 51% of patients (Study 2). In clinical trials with vinorelbine administered at 30 mg/m2 per week, neutropenia resulted in hospitalizations for pyrexia and/or sepsis in 8% of patients. Death due to sepsis occurred in 1% of patients. Neutropenia nadirs occur between 7 and 10 days after dosing with neutropenia count recovery usually occurring within the following 7 to 14 days.
Monitor complete blood counts prior to each dose of vinorelbine. Do not administer vinorelbine to patients with neutrophil counts <1,000 cells/mm3. Adjustments in the dosage of vinorelbine should be based on neutrophil counts obtained on the day of treatment .
Drug-induced liver injury manifest by elevated aspartate aminotransferase (AST) and bilirubin occur in patients receiving vinorelbine as a single agent and in combination with cytotoxic agents. Assess hepatic function prior to initiation of vinorelbine and periodically during treatment. Reduce the dose of vinorelbine for patients who develop elevations in total bilirubin
≥ 2 times upper limit of normal .
Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners. …
Vinorelbine side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Myelosuppression
Hepatic Toxicity
Severe Constipation and Bowel Obstruction
Extravasation and Tissue Injury
Neurologic Toxicity
Pulmonary Toxicity and Respiratory Failure
Because clinical trials are conducted under varying designs and in different patient populations, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial and may not reflect the rates actually observed in clinical practice.
Single Agent
The data below reflect exposure to vinorelbine as a single agent administered at a dose of 30 mg/m2 on a weekly basis to 365 patients enrolled in 3 controlled studies for metastatic NSCLC and advanced breast cancer. The population included 143 patients with previously untreated metastatic NSCLC (Study 3) who received a median of 8 doses of vinorelbine. The patients were aged 32 to 79 (median 61 years), 71% were male, 91% White, 48% had adenocarcinoma histology. The data also reflect exposure to vinorelbine in 222 patients with previously treated advanced breast cancer who received a median of 10 doses of vinorelbine. Vinorelbine is not indicated for the treatment of breast cancer.
Selected adverse reactions reported in these studies are provided in Tables 1 and 2. …
Drug interactions
Exercise caution in patients concurrently taking drugs known to inhibit CYP3A. Concurrent administration of vinorelbine with a CYP3A inhibitor may cause an earlier onset and/or an increased severity of adverse reactions.
About this medicine
Vinorelbine Injection, USP contains vinorelbine, a semi-synthetic vinca alkaloid. The molecular formula for vinorelbine tartrate is C45H54N4O8•2C4H6O6. It has a molecular weight of 1079.11. The structural formula is as follows:
Vinorelbine tartrate is a white to light yellow amorphous powder. It is easily soluble in water, very soluble in methanol and practically insoluble in hexane.
Vinorelbine Injection, USP is a sterile nonpyrogenic aqueous solution for intravenous use. Each milliliter of solution contains 10 mg vinorelbine (equivalent to 13.85 mg vinorelbine tartrate) in Water for Injection, USP. The pH of Vinorelbine Injection, USP is approximately 3.5.
How it works: Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 10a70995-e04d-4044-b1dc-c9aa27460397. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate